(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
6 May 2005 (06.05.2005)

PCT

(10) International Publication Number
WO 2005/040168 A1

(51) International Patent Classification[7]: C07D 471/16, A61K 31/55, C07D 471/16 // (C07D 243/00, 221:00, 209:00)

(21) International Application Number: PCT/IB2004/003406

(22) International Filing Date: 18 October 2004 (18.10.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
03292660.2 24 October 2003 (24.10.2003) EP

(71) Applicant *(for all designated States except US)*: **WARNER-LAMBERT COMPANY LLC** [US/US]; 201 Tabor Road, Morris Plains, NJ 07950 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **DEVILLERS, Ingrid** [BE/FR]; c/o Pfizer Limited, European Pharma Patent Department, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB). **GAUDILLIERE, Bernard** [FR/FR]; c/o Pfizer Limited, European Pharma Patent Department, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB). **JACOBELLI, Henry** [FR/FR]; c/o Pfizer Limited, European Pharma Patent Department, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB). **PEVET, Isabelle** [FR/FR]; c/o Pfizer Limited, European Pharma Patent Department, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).

(74) Agents: **FULLER, Grover** et al.; c/o WOOD, David, J., Pfizer Research and Development, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2005/040168 A1

(54) Title: AZABENZODIAZEPINES AS PHOSPHODIESTERASE-4 INHIBITORS



(I)

(57) Abstract: Compounds of formula (I): characterized in that: • R_1 represents a group selected from hydrogen atom, methyl, methoxy, hydroxy, amino, dimethylamino, acetamido, pyrrolidin-l-yl, and hydroxymethyl; • R_2 represent a group selected from phenyl, pyridyl, pyrimidyl, quinolyl, isoquinolyl, indolyl, pyrolyl, [1,2,3]-triazolyl, benzo[c]isoxazolyl, thienyl, pyrazolyl, isothiazolyl, imidazolyl, benzofuranyl, pyrazolo[5,1-c][1,2,4]triazyl each of these groups being optionally substituted from 1 to 3 groups, identical or different independently of each other, selected from halogen, trifluoromethyl, (C1-C4)alkyl, (C_1-C4)alkoxy, hydroxy, amino, acetamido, tert-butyloxycarbonylamino, cycloalkyl-carbonylamino, sulfonamide, nitro, acetylmethoxy, cyclopentyloxy; optionally, their optical isomers, and addition salts thereof with a pharmaceutically acceptable acid or base, and their use as active ingredient in pharmaceutical composition useful for treating diseases involving therapy by inhibition of PDE4.